Noble Financial Increases Adamas Pharmaceuticals, Inc. (ADMS) Price Target to $48.00
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) had its target price boosted by research analysts at Noble Financial from $33.00 to $48.00 in a report released on Wednesday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Noble Financial’s price target indicates a potential upside of 72.97% from the company’s current price.
A number of other equities research analysts have also recently commented on ADMS. BidaskClub cut Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 17th. ValuEngine raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Piper Jaffray Companies reissued an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a report on Wednesday, September 20th. JMP Securities reissued an “outperform” rating and set a $33.00 price target (up from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Finally, Mizuho reissued a “buy” rating and set a $48.00 price target (up from $26.00) on shares of Adamas Pharmaceuticals in a report on Wednesday, September 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $42.00.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up $0.39 during trading on Wednesday, reaching $27.75. The company had a trading volume of 484,156 shares, compared to its average volume of 1,170,000. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41. Adamas Pharmaceuticals has a one year low of $13.50 and a one year high of $29.29.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.01) by ($0.03). The firm’s quarterly revenue was down 99.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.66) earnings per share. analysts forecast that Adamas Pharmaceuticals will post -3.87 earnings per share for the current year.
Several institutional investors have recently modified their holdings of the company. Axiom International Investors LLC DE grew its position in shares of Adamas Pharmaceuticals by 134.1% during the third quarter. Axiom International Investors LLC DE now owns 236,209 shares of the specialty pharmaceutical company’s stock valued at $5,001,000 after purchasing an additional 135,297 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Adamas Pharmaceuticals by 13,028.4% during the third quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after purchasing an additional 135,235 shares in the last quarter. FNY Partners Fund LP purchased a new position in shares of Adamas Pharmaceuticals during the third quarter valued at about $231,000. EAM Investors LLC purchased a new position in shares of Adamas Pharmaceuticals during the third quarter valued at about $1,795,000. Finally, Hikari Power Ltd purchased a new position in shares of Adamas Pharmaceuticals during the third quarter valued at about $635,000. Hedge funds and other institutional investors own 71.83% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.